share_log

基石藥業-B:董事會會議日期

CSTONE PHARMA-B: DATE OF BOARD MEETING

香港交易所 ·  Mar 14 05:00
Summary by Moomoo AI
基石藥業-B(「本公司」)宣布將於2024年3月27日(星期三)召開董事會會議,目的是考慮及批准公司及其附屬公司截至2023年12月31日止年度的全年業績並進行發佈。會議將由公司主席兼非執行董事李偉博士主持,其他董事會成員包括執行董事楊建新博士、非執行董事Kenneth Walton Hitchner III先生、林向紅先生及胡正國先生,以及獨立非執行董事Paul Herbert Chew博士、胡定旭先生及孫洪斌先生。此次會議的召開,將為投資者提供公司最新的財務表現概況。
基石藥業-B(「本公司」)宣布將於2024年3月27日(星期三)召開董事會會議,目的是考慮及批准公司及其附屬公司截至2023年12月31日止年度的全年業績並進行發佈。會議將由公司主席兼非執行董事李偉博士主持,其他董事會成員包括執行董事楊建新博士、非執行董事Kenneth Walton Hitchner III先生、林向紅先生及胡正國先生,以及獨立非執行董事Paul Herbert Chew博士、胡定旭先生及孫洪斌先生。此次會議的召開,將為投資者提供公司最新的財務表現概況。
KEYSTONE PHARMACEUTICAL-B (THE “COMPANY”) ANNOUNCES THAT A BOARD MEETING WILL BE HELD ON WEDNESDAY, MARCH 27, 2024 FOR THE PURPOSE OF CONSIDERING AND APPROVING AND PUBLISHING THE ANNUAL RESULTS OF THE COMPANY AND ITS SUBSIDIARIES FOR THE YEAR ENDED DECEMBER 31, 2023. The meeting will be chaired by the Company's Chairman and Non-Executive Director, Dr. Li Wai, and other Board members will include Executive Director Dr. Yang Jianxin, Non-Executive Director Mr. Kenneth Walton Hitchner III, Mr. Lin Xianghong and Mr. Hu Zhengguo, as well as Independent Non-Executive Directors Dr. Paul Herbert Chew, Mr. Wu Ding Xu and Mr. Sun Hung Bin. The meeting will provide investors with an updated overview of the company's financial performance.
KEYSTONE PHARMACEUTICAL-B (THE “COMPANY”) ANNOUNCES THAT A BOARD MEETING WILL BE HELD ON WEDNESDAY, MARCH 27, 2024 FOR THE PURPOSE OF CONSIDERING AND APPROVING AND PUBLISHING THE ANNUAL RESULTS OF THE COMPANY AND ITS SUBSIDIARIES FOR THE YEAR ENDED DECEMBER 31, 2023. The meeting will be chaired by the Company's Chairman and Non-Executive Director, Dr. Li Wai, and other Board members will include Executive Director Dr. Yang Jianxin, Non-Executive Director Mr. Kenneth Walton Hitchner III, Mr. Lin Xianghong and Mr. Hu Zhengguo, as well as Independent Non-Executive Directors Dr. Paul Herbert Chew, Mr. Wu Ding Xu and Mr. Sun Hung Bin. The meeting will provide investors with an updated overview of the company's financial performance.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more